How can we know early who will benefit from tumor target therapy?

November 21, 2007

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge. The goal is to only administer treatments that have a high probability of being effective. Modern cancer care is critically dependent on imaging technologies, which are used to detect tumors early, when they are easier to treat, and to guide therapy or surgery.

Vascular endothelial growth factor (VEGF) and EGFR inhibitors have become key components of therapies for several tumor types. Close relationships between these two factors exist: VEGF signaling is up-regulated by EGFR expression and, conversely, VEGF up-regulation independent of EGFR signaling seems to contribute to resistance to EGFR inhibition. Therefore, inhibition of both pathways could improve anti-tumor efficacy and overcome resistance to EGFR inhibition.

A research article to be published in the December 7 issue of the World Journal of Gastroenterology addresses this question. The research team, led by Dr. Sun from Minnan PET Center, used FDG PET/CT to monitor early responses, followed by EGF-receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar) treatment.

One conclusion reported by the investigators is that molecular imaging could monitor molecular treatment, and that the combination of EGFR-specific antibodies with VEGF-specific antibodies may be a promising combination for palliative treatment.

Another interesting conclusion is the potential of this novel approach to anticancer therapy. Monitoring responses algorithm by PET/CT will be elucidated by large, ongoing clinical trials. Molecular imaging continues to tell us the exciting results of molecular therapy for cancer.

Source: World Journal of Gastroenterology

Explore further: Candidate drug may be effective against broader class of brain cancers

Related Stories

Candidate drug may be effective against broader class of brain cancers

July 9, 2018
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor (EGFR), a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed ...

New study points to a potential 'Achilles heel' in brain cancer

June 4, 2018
Scientists at Virginia Commonwealth University believe they have uncovered an "Achilles heel" of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. Their study published this week in the Proceedings ...

Molecular tumor markers could reveal new therapeutic targets for lung cancer treatment

October 30, 2014
Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of ...

Molecular marker predicts patients most likely to benefit longest from two popular cancer drugs

September 5, 2013
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...

Genetic composition of multicentric lung tumors appears to be similar

January 9, 2012
Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...

A study of fruit fly genes reveals how molecules cooperate to induce tumor formation

December 5, 2012
Cancer biologists have known for decades that even the most potent cancer-causing genes do not act alone. Yet, identifying which combinations of genetic changes can cause a tumor to form and disease to progress remains a ...

Recommended for you

Link found between bitter-taste sensitivity and cancer risk

July 18, 2018
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been ...

Study finds melanoma biomarkers predicting checkpoint blocker response

July 18, 2018
Scientists at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood ...

Scientists discover a mechanism of drug resistance in breast and ovarian cancer

July 18, 2018
There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...

Research identifies new breast cancer therapeutic target

July 18, 2018
Research led by Suresh Alahari, Ph.D., Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an ...

Cancer patients may experience delayed skin effects of anti-PD-1 therapy

July 18, 2018
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment ...

Early supper associated with lower risk of breast and prostate cancer

July 18, 2018
Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 p.m. or ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.